

## PharmaMar leads the ONCOLIBERYX consortium together with four research centers to develop new marine-based oncology drug administration strategies

- **The project, given the necessity for public-private collaboration projects, approved by the Ministry of Science and Innovation, has a financing of €3.49 million from funds from the Recovery, Transformation and Resilience Plan.**

**Madrid, December 2<sup>nd</sup>, 2022.** – The ONCOLIBERYX project, led by PharmaMar (MSE:PHM), brings together four leading Spanish research groups in nanotechnology and oncology, to develop unique formulations that could lead to new oncology therapies based on the marine compounds in PharmaMar's collection.

The consortium relies on the experience and expertise of renowned Spanish researchers in the field of new drug delivery systems, immunotherapy and cancer, such as Professors María José Alonso (University of Santiago de Compostela), María Blanco (University of Navarra), Ignacio Melero (Cima University of Navarra) and José Luis Pedraz (University of the Basque Country).

Today, cancer is the second leading cause of death in developed Western countries. Despite remarkable advances in the elucidation of the biological mechanisms underlying this disease and new therapeutic approaches, concerns about the side effects caused by these drugs are driving research into more selective and effective therapeutic regimens and formulations.

ONCOLIBERYX focuses on the search for new drug delivery strategies, in order to increase the specificity of oncological active compounds, decreasing their toxicity and side effects, while maintaining and/or increasing their therapeutic effects.

**Pilar Calvo, Ph.D.**, Head of Analytical and Pharmaceutical Development at PharmaMar and technical coordinator of the project, emphasizes that *"in the last 20 years, drug nanocarriers - liposomes, lipid and polymeric nanoparticles, micelles, antibody-drug conjugates, etc. - have demonstrated notable advantages in meeting these challenges. The research resulting from PharmaMar's collaboration with these innovative research groups will undoubtedly lead to progress in the search for more effective and safer drugs."*

#### Legal warning

This press release does not constitute an offer to sell or the solicitation of an offer to buy securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction.

#### About PharmaMar

PharmaMar is a biopharmaceutical company focused on the research and development of new oncology treatments, whose mission is to improve the healthcare outcomes of patients afflicted by serious diseases with our innovative medicines. The Company is inspired by the sea, driven by science, and motivated by patients with serious diseases to improve their lives by delivering novel medicines to them. PharmaMar intends to continue to be the world leader in marine medicinal discovery, development and innovation. PharmaMar has developed and now commercializes Yondelis® in Europe by itself, as well as Zepzelca® (lurbinectedin), in the US; and Aplidin® (plitidepsin), in Australia, with different partners. In addition, it has a pipeline of drug candidates and a robust R&D oncology program. PharmaMar has other clinical-stage programs under development for several types of solid cancers: lurbinectedin and ecubectedin. Headquartered in Madrid (Spain), PharmaMar has subsidiaries in Germany, France, Italy, Belgium, Austria, Switzerland and The United States. PharmaMar also wholly owns Sylentis, a company dedicated to researching therapeutic applications of gene silencing (RNAi). To learn more about PharmaMar, please visit us at [www.pharmamar.com](http://www.pharmamar.com).

#### Media Contact:

Lara Vadillo – Communication Director [lvadillo@pharmamar.com](mailto:lvadillo@pharmamar.com).  
Miguel Martínez-Cava – Comm. Manager [mmartinez-cava@pharmamar.com](mailto:mmartinez-cava@pharmamar.com)  
Phone: +34 918466000

#### Capital Markets & Investor Relations:

José Luis Moreno – Capital Markets & Investor Relations Director  
Natalia Amo – Capital Markets & Investor Relations  
[investorrelations@pharmamar.com](mailto:investorrelations@pharmamar.com)  
Phone: +34 914444500



Or please visit our website at [www.pharmamar.com](http://www.pharmamar.com)

